<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313183</url>
  </required_header>
  <id_info>
    <org_study_id>137-162</org_study_id>
    <nct_id>NCT00313183</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SYMLIN in Adolescent Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes
      mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and
      physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics of Symlin in adolescent subjects with type 1 diabetes</measure>
    <time_frame>single doses</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of Symlin in adolescent subjects with type 1 diabetes</measure>
    <time_frame>single doses</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of Symlin compared to placebo in adolescent subjects with type 1 diabetes on various pharmacodynamic endpoints</measure>
    <time_frame>single doses</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single doses of pramlintide acetate or placebo, given in three different sequences to three cohorts of subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramlintide acetate</intervention_name>
    <description>single subcutaneous doses of 15mcg and 30mcg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Symlin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 1 diabetes mellitus for at least 1 year prior to screening

          -  Be on a stable regimen requiring multiple daily injections of basal and mealtime
             insulin or continuous subcutaneous insulin infusion for at least 2 weeks prior to
             screening

          -  HbA1c between 6.0% and 10.0%, inclusive, at screening

          -  Body weight &gt;=50 kg at screening

        Exclusion Criteria:

          -  Currently being treated with the following medications: *Any oral antihyperglycemic
             agent; *Drugs that directly affect gastrointestinal motility

          -  Has been previously treated with Symlin/pramlintide (or has participated in a
             Symlin/pramlintide clinical study)

          -  Has received any investigational drug within 1 month of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Porter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amylin Pharmaceuticals, LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2006</study_first_submitted>
  <study_first_submitted_qc>April 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>pediatric</keyword>
  <keyword>pramlintide</keyword>
  <keyword>Symlin</keyword>
  <keyword>Amylin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

